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marketed lapatinib, which has the highest consumption among the most expensive 
drugs in Norway and Slovakia. ConClusions: Countries with lower GDP have less 
availability of anticancer medicines in amount and in quantity. Countries with 
lower GDP must control the usage of drugs for malignancy treatemnt if they want 
to allocated their resurses for treatment of other diseases as well.
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objeCtives: Accurate estimates of the number of advanced (Stage IIIb and Stage 
IV) non-small cell lung cancer (ADV-NSCLC) patients are needed to estimate the 
potential clinical and economic outcomes of new targeted therapies for ADV-NSCLC. 
The objective of this study was to forecast counts of squamous/non-squamous 
cell patients eligible for first- through third-line treatment yearly from 2015-2019 
in EU countries. Methods: Segmented linear regression (“joinpoint”) was used 
to forecast age- and gender-stratified lung cancer incidence rates from histori-
cal (year 2000+) population-based cancer registry data over the next five-years. 
Yearly incident case count totals by country were apportioned according to NSCLC 
morphology and stage at diagnosis. Early to advanced stage progression rates were 
estimated over a 10-year interval. Advanced patients receiving systemic treat-
ment were further stratified by histology and line of treatment to obtain counts. 
A probabilistic sensitivity analysis (PSA) was used to estimate variability in the 
patient counts. Results: By histology, the forecasted number of squamous and 
non-squamous ADV-NSCLC patients receiving first-line treatment in 2015 were: 
Germany = 13,300 and 21,200; UK = 8,400 and 21,300; France = 11,800 and 18,800; 
Italy = 7,600 and 20,500; Spain = 7,100 and 11,400. Combined across both histolo-
gies, the numbers of patients receiving second- and third-line treatment in 2015 
were: Germany = 17,400 and 4,400; UK 15,500 and = 4,000; France = 15,500 and 4,000; 
Italy = 14,600 and 3,800; Spain = 9,400 and 2,400. The projected numbers of deaths 
due to ADV-NSCLC in 2015 were: Germany = 35,300; UK = 27,700; France = 30,800; 
Italy = 27,400; Spain = 19,500. ConClusions: These results represent the first 
published data to estimate the current and future number of patients eligible for 
targeted ADV-NSCLC therapies in the EU-5. Despite declining incidence trends, there 
remains a significant unmet clinical need for ADV-NSCLC treatments to reduce 
high mortality rates.
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objeCtives: Patient access schemes (PAS) give UK patients access to medicines not 
normally funded by the National Institute for Health and Care Excellence (NICE) and 
balance company profits and competitiveness with government interests to ensure 
availability of medicines at reasonable prices. In April 2011 the NHS payer funded 
Cancer Drugs Fund (CDF) was introduced in England to further improve access to 
life saving cancer medicines not approved by NICE. The objective of this study was 
to determine whether access to new, non-NICE funded oncology medicines contin-
ues to rely on the relatively cost effective PAS or increasingly depends on the more 
costly NHS payer funded CDF. Methods: A search was undertaken for all NICE- or 
Scottish Medicines Consortium (SMC)-approved HTAs incorporating a PAS (PAS-
HTAs) 4 years before and after introduction of the CDF. In addition, all medicines 
approved for use under the CDF were identified. Results: Fifty five of 128 NICE- or 
SMC-approved PAS-HTAs between October 2007 and June 2015 were in oncology. Of 
these, 10 NICE and 4 SMC PAS-HTAs had been approved prior to, whereas 17 NICE 
and 24 SMC PAS-HTAs had been approved after introduction of the CDF, amount-
ing to an almost 6-fold increase in SMC PAS-HTAs but a less than 2-fold increase 
in NICE PAS-HTAs over a similar period. However, 7 oncology medicines receiving 
HTA approval by the SMC but not NICE were included in the May 2015 CDF list of 
approved medicines. ConClusions: Since the introduction of the CDF, there has 
been a discrepancy between the number of PAS-HTAs in cancer treatments between 
NICE and the SMC. For selected medicines, the CDF appears not to have improved 
access to oncology products as part of PAS-HTAs but rather lead to increased costs 
to health service payers.
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objeCtives: The mode by which patients receive information may impact their 
perception of drugs and consequently their compliance. This study aims to meas-
ure how different presentation factors (format - textual, tabular, graphical; order 
of presenting risks and benefits) and patient characteristics can impact percep-
tion of a drug’s risks and benefits. Methods: Data were collected via an online 
questionnaire presenting two drug options to patients in three therapeutic areas: 
atrial fibrillation, breast cancer, diabetes. Two questions were asked on the safety 
and the willingness to take the drug. A novel Generalized Estimating Equation 
method for correlated multinomial data proposed by Touloumis et al., 2013 was 
used to create an ordinal cumulative link model for the questions on perception. 
Factors controlled for were: presentation format, order of presentation of risks and 
benefits, comprehension of drug’s effects by the subject, order of presentation of 
different formats, current mood, and demographic characteristics. Results: Drug 
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objeCtives: The aim of this study was to assess basal cell carcinoma (BCC) 
prevalence in real practice, and to calculate the related healthcare resources 
consumption. Methods: An observational retrospective cohort analysis based 
on administrative databases of three Italian Local Health Units was conducted. 
Beneficiaries who have been hospitalised for BCC (ICD-9 code 173) or with a histo-
logical diagnosis (ICD-O M8090/3-8093/3) from January 1st, 2009 to December 31st, 
2013 - index date - were included. Patients were characterised back to Jan 2009, and 
followed up till the end of the observation period (Dec 2013) to assess healthcare 
resource consumption. Results: According to preliminary findings on around 
550’000 beneficiaries, BCC prevalence through discharge diagnosis was around 6 
cases every 10.000 patients/year; considering also pathological anatomy database, 
10 cases of BCC every 10.000 patients/year were reported. Advanced patients (aBCC) 
were reported to be around 4%, most of them defined according to the following 
criteria: two surgical excisions on the same side and at least one subsequent proce-
dure (surgery, radiotherapy, photodynamic therapy or imiquimod), 0,3% of enrolled 
patients had metastasis.During follow-up, ambulatory surgery was performed in 
63.5% of advanced patients, around 1.6% underwent radiotherapy and 38.1% of 
them had at least one hospital admission; imiquimod was prescribed in 11.1% of 
patients. Yearly aBCC patients resource expenditure was around 404€ for hospitali-
sations - index costs excluded - 32€ for ambulatory care and 77€ for drugs (anti-
inflammatories, antibiotics and topic drugs; 16€ for imiquimod). ConClusions: As 
BCC patients are reported to have a low recurrence of hospitalisations, discharge-
based analysis would underestimate real prevalence. With pathological anatomy 
database, this study estimated 0.4 advanced BCC cases/10’000 beneficiaries/year. 
Healthcare consumption in this sub-population was driven by hospitalisations and 
ambulatory costs due to surgical excision
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objeCtives: Vandetanib, approved in 2012 in Canada, is indicated for the treatment 
of advanced medullary thyroid cancer. QTc-prolongation or torsade de pointes is 
considered in the risk management plan as an identified risk. To minimize this risk 
a restricted distribution program (RDP) has been implemented. Although shown 
effective, there are limited data on its associated burden to patients, health care 
professionals and the healthcare system. The objectives of the present study are 
to evaluate qualitatively and quantitatively the burden associated with the differ-
ent components of the vandetanib RDP and, to determine the economic impact of 
the program for the healthcare system. Methods: A mixed method evaluation 
has been used. Burden was determined by comparing prescribing and monitoring 
practices under the RDP with those that would have been observed in the absence 
of the RDP. Data on healthcare usage were collected through interviews conducted 
in convenient samples of HCPs (prescribers, pharmacists and nurses) either exposed 
to the RDP or not yet certified for the vandetanib RDP (i.e., unexposed) but familiar 
with the treatment of medullary thyroid cancer. A mapping of patient journeys, with 
and without the RDP, was developed to identify major components of the program. 
An economic evaluation, considering the perspective of the third party payers com-
pleted this analysis. Avoidable costs corresponded to those associated with activi-
ties deemed redundant with routine oncology care. Results: Major components 
of the vandetanib RDP have been identified as well as areas of redundancies with 
standard oncology care. For each component, the qualitative burden for HCPs and 
ultimately patients was determined along with its associated costs considering 
the third party payers perspective. ConClusions: Risk minimisation measures 
should avoid duplication of efforts and loss of economic resources. Evaluation of 
burden, key to optimize the effectiveness of risk management plans, should be 
conducted systematically.
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objeCtives: Consumption and expenditure of drugs for malignancy varies between 
countries. One of the main reason is the high price of this innovative drugs. 
Developed countries have more resources for the treatment of malignant diseases 
and better access to expensive drugs than countries with midle income. Methods: 
We compared the data on expenditure and consumption of innovative anticancer 
drugs in middle income country Serbia (13,020 USD), and high income country 
with different GDP: Slovakia (26,497USD) and Norway (64,406 USD) during the year 
2012. Consumption data were expressed in grams of active ingredient per million 
in one year, expenditure in EU. Results: In Norway 144 drugs for malignancy is 
on market, while in Serbia only 92 drugs are available for ttreatemnt of malignancy. 
In Norway in year 2012 440 million eur was spent for drugs for malignancy, or 
about 80 million euros per million inhabitans. Slovakia had more than half lower 
consumption of anticancer medicines, 190 million euros, or about 37 million euros 
per million inhabitants. In Serbia only 73 million euros was spent for anticancer 
drugs, or about 10 million euros per million ihabitants, which is much less com-
pared to the other two countries. Data on consumption 10 most expensive oncology 
drugs, show that the least of these drugs are consumed in Serbia when comparing 
to Norway and Slovakia. Among them, the most frequently used drug in Serbia 
is trastuzumab(treatment of metastatic breast cancer). For this indication is also 
